Bromazolam Blister 10x 2.5mg ten-tablet research material packaging
Bromazolam Blister - 10x 2.5mg Price range: € 25,90 through € 198,75
Back to products
Bromonordiazepam Blister - 10x 2.5mg
Bromonordiazepam Blister - 10x 2.5mg Price range: € 25,90 through € 218,75

Bromonordiazepam Pellets – 2.5mg

Price range: € 15,00 through € 310,00

Bromonordiazepam Pellets 2.5mg are described as compressed research pellets containing a nominal 2.5 mg of bromonordiazepam per unit.

Bromonordiazepam is a brominated 1,4-benzodiazepine-related compound described in the source as desalkyl-gidazepam, a metabolite associated with gidazepam.

The supplied specifications identify the systematic name 7-bromo-5-phenyl-1,3-dihydro-2H-1,4-benzodiazepin-2-one, CAS number 2894-61-3, molecular formula C15H11BrN2O, and molecular weight approximately 315.16 g/mol.

The source describes compressed pellets supplied in resealable packaging and reports an ingredient-purity specification of at least 98% by HPLC.

It also claims batch traceability, third-party laboratory testing, and pellet-weight consistency within ±2%.

These specifications require verification against batch-specific records.

No actual Certificate of Analysis, finished-pellet assay, or content-uniformity dataset was supplied.

The nominal 2.5 mg label claim therefore does not establish verified ingredient content in each pellet.

Benzodiazepine-related hazards include sedation, impaired coordination, dependence, and dangerous interactions with other central nervous system depressants.

For research use only. Not for human or veterinary use. Not for clinical, diagnostic, or consumptive applications.

SKU: CERT-P-12455 Category:
Description

Bromonordiazepam Pellets 2.5mg – Research Material Information

Bromonordiazepam Pellets 2.5mg – Product Overview

The supplied product is described as compressed research pellets containing bromonordiazepam, a brominated benzodiazepine-related compound.

Each pellet carries a nominal label claim of 2.5 mg.

The stated content is not an independently verified finished-pellet assay result.

The source associates this material with laboratory investigation of benzodiazepine chemical identity, structural characterization, chromatographic behavior, and analytical documentation.

No batch-specific Certificate of Analysis or independent laboratory report was provided.

The material has not been established as a certified reference standard or approved pharmaceutical product.

Chemical Identity & Classification

Bromonordiazepam belongs to the 1,4-benzodiazepine structural class.

The source identifies it as a desalkyl-gidazepam metabolite and provides the following chemical specifications:

  • Reported compound: Bromonordiazepam
  • Supplied systematic name: 7-Bromo-5-phenyl-1,3-dihydro-2H-1,4-benzodiazepin-2-one
  • Reported CAS number: 2894-61-3
  • Molecular formula: C15H11BrN2O
  • Reported molecular weight: 315.16 g/mol
  • Product form: Compressed pellets
  • Nominal content: 2.5 mg per pellet
  • Designation: Research Use Only

The formula corresponds to approximately 315.17 g/mol, consistent with the reported molecular weight within rounding.

However, numerical agreement does not independently confirm the chemical identity or composition of a physical sample.

The CAS assignment, systematic name, and metabolite designation should be checked against authoritative chemical records.

Public chemical-reference information can be reviewed through PubChem.

Chemical & Physical Characteristics

The source describes a compressed pellet presentation.

No verified pellet dimensions, appearance specifications, excipient composition, hardness measurements, or disintegration data were supplied.

The product brief refers to solubility profiles, dissolution characteristics, and stability under analytical conditions.

These properties can depend on the chemical form, excipients, and manufacturing characteristics of the finished pellet.

No validated measurements were supplied to establish specific dissolution performance or quantitative recovery.

A standardized pellet appearance or mass does not independently establish uniform ingredient distribution.

Purity & Analytical Verification

The source reports an ingredient-purity specification of at least 98% by HPLC.

It also claims identity confirmation using HPLC, mass spectrometry, and NMR spectroscopy.

No chromatograms, mass spectra, NMR records, impurity reports, or batch-specific Certificate of Analysis were provided.

The claimed purity remains unverified.

Ingredient purity and finished-pellet content are separate analytical measurements.

A high-purity ingredient does not establish that every compressed pellet contains exactly 2.5 mg of bromonordiazepam.

The source describes potential laboratory analytical applications, but no certified quantitative reference value or validated finished-product performance has been demonstrated.

Quality Control & Batch Integrity

The source claims comprehensive batch testing, third-party verification, traceability, residual-solvent analysis, and pellet-weight consistency within ±2%.

These claims require supporting batch records.

No independent laboratory report, pellet-weight dataset, content-uniformity report, or residual-solvent analysis was supplied.

Pellet-weight variation measures the consistency of total pellet mass.

It does not independently establish the uniformity of active-ingredient content.

A Research Use Only designation is not evidence of certified reference-material status or validated analytical performance.

Safety, Handling & Laboratory Precautions

Bromonordiazepam is associated with benzodiazepine-related central nervous system depressant hazards.

Potential risks include sedation, impaired coordination, dependence, withdrawal complications, and respiratory depression.

Combining benzodiazepine-related substances with opioids, alcohol, or other central nervous system depressants can substantially increase the risk of severe harm.

No verified product-specific Safety Data Sheet was provided.

Institutional safety procedures should address restricted access, appropriate protective equipment, secure custody, accidental-exposure response, contamination prevention, and waste management.

The pellet presentation does not establish suitability for human or veterinary administration.

Packaging, Labeling & Storage

The source describes compressed pellets supplied in resealable packaging.

No verified packaging specification or finished-product stability study was supplied.

The suggested storage range is approximately 2–8°C, with protection from moisture and light.

No supporting stability data were provided to establish this range as a validated requirement.

The source also does not establish a verified shelf life or packaging-protection performance.

Laboratory inventory documentation should distinguish nominal product specifications from batch-verified analytical results.

Intended Research Use & Market Positioning

The source describes analytical laboratory contexts involving benzodiazepine chemical identity, structural comparison, and forensic characterization.

No certified reference-material status or validated quantitative performance has been demonstrated.

The supplied Raw Lab Chems catalog references include Bromonordiazepam Pellets, Bromonordiazepam Powder, and Bromonordiazepam Blister 10x 2.5mg.

These links refer to different product presentations.

Their formulation equivalence, ingredient purity, and finished-product analytical performance have not been independently established.

A shared compound name does not demonstrate equivalent formulations or interchangeable analytical properties.

Ordering, Availability & Fulfillment

The source claims international shipping, tracking, customs documentation, and compliant transport.

No current inventory record, carrier authorization, transport assessment, or shipment documentation was provided.

The source also refers to IATA and DOT compliance.

No applicable dangerous-goods classification or supporting compliance documentation was supplied.

Accordingly, worldwide shipment, customs clearance, and regulatory authorization cannot be assumed.

The legal treatment of bromonordiazepam may vary by jurisdiction.

Research-only labeling does not create an exemption from applicable laws.

Legal & Regulatory Disclaimer

For research use only. Not for human or veterinary use. Not for clinical, diagnostic, or consumptive applications.

Bromonordiazepam is a benzodiazepine-related compound whose acquisition, possession, transportation, importation, exportation, and laboratory investigation may be regulated.

Institutions remain responsible for determining applicable legal requirements, obtaining necessary authorization, and maintaining appropriate laboratory safety and secure custody.

No therapeutic approval, consumer-use authorization, or certified analytical status is implied.

Additional information
Quantity (pellets)

25

,

50

,

100

,

250

,

500

,

1000

Reviews (0)

Reviews

There are no reviews yet.

Be the first to review “Bromonordiazepam Pellets – 2.5mg”
Shipping & Delivery